The use of gabapentin in the management of postoperative pain after total hip arthroplasty: a meta-analysis of randomised controlled trials by unknown
REVIEW Open Access
The use of gabapentin in the management
of postoperative pain after total hip
arthroplasty: a meta-analysis of randomised
controlled trials
Chao Han1†, Xiao-dan Li2†, Hong-qiang Jiang1†, Jian-xiong Ma1 and Xin-long Ma1*
Abstract
Background: Pain management after total hip arthroplasty (THA) varies and has been widely studied in recent
years. Gabapentin as a third-generation antiepileptic drug that selectively affects the nociceptive process has been
used for pain relief after THA. This meta-analysis was conducted to examine the efficacy of gabapentin in THA.
Methods: An electronic-based search was conducted using the following databases: PubMed, EMBASE, Ovid MEDLINE,
ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials (CENTRAL). Randomised controlled trials (RCTs)
involving gabapentin and a placebo for THA were included. The meta-analysis was performed following the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
Results: Five trials met the inclusion criteria. The cumulative narcotic consumption and the visual analogue scale (VAS)
scores at 24 and 48 h postoperatively were used for postoperative pain assessment. There was a significant decrease in
morphine consumption at 24 h (P = 0.00). Compared with the control group, the VAS score (at rest) at 48 h was less in
the gabapentin group (P = 0.00).
Conclusion: The administration of gabapentin is effective in decreasing postoperative narcotic consumption and the
VAS score.
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Background
Total hip arthroplasty (THA) is a common and success-
ful surgery in modern medicine, but it is often associated
with intense postoperative pain [1]. Pre-emptive analgesia
might be a good way to relieve the postoperative pain in
the clinic. However, effective treatment of postoperative
pain continues to be a challenge for orthopaedists because
poor control of postoperative pain can have negative
effects on the pulmonary system and cardiovascular
system, which can influence surgical outcomes, and it
has been reported that the treatment of postoperative
pain often remains insufficient [2].
The management of pain after THA is often directed
at the reduction of pain and reducing morphine require-
ments by multimodal analgesia techniques [3]. Despite
the multimodal approach, some patients may develop
intractable postoperative pain [4, 5]. Currently, certain
doses of opioids through patient-controlled analgesia
(PCA) devices are often used for postoperative analgesia
after THA [6, 7]. Although not every patient needs the
additional non-opioid, the use of an additional non-opioid
agent is often recommended, given the various side effects
of analgesic opioids [8]. One of the agents used is gaba-
pentin, which is a third-generation antiepileptic drug that
selectively affects the nociceptive process [9]. It has not
only the central and peripheral antalgic activity but also
the relatively well-tolerated property [10]. In addition to
gabapentin, the non-steroidal anti-inflammatory drugs
(NSAIDS) as the non-opioids were also used for THA.
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However, the adverse effects on the gastrointestinal and
haematological systems as well as on the renal func-
tions were easily found once NSAIDS combined with
opioids.
In previous years, some studies were placed to esti-
mate the effects of pre-emptive gabapentin before sur-
gery [11–14]. Although some studies have made their
own conclusions, the role of gabapentin in postoperative
pain relief after THA has not been investigated through a
meta-analysis. The aim of this work was to investigate the
effect of the gabapentin and make a better understanding
of the efficacy and safety of gabapentin in the manage-
ment of postoperative pain after THA.
Methods
This study followed the guidelines of the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement [15]. We conducted an
electronic-based search using the following databases:
MEDLINE, PubMed, EMBASE, and Cochrane Central
Register of Controlled Trials. The following medical sub-
ject heading terms, keywords, and their combinations were
used: “pain management, postoperative pain, total hip
arthroplasties, total hip replacement, and gabapentin”. The
search was limited to randomised controlled trials (RCTs)
in humans and published in English up to December 2015.
The flow chart of study selection is shown in Fig. 1.
Fig. 1 The selection of literature for included studies
Table 1 Characteristics of included studies
Clinical trials Age(years) Gender (M/F) Location No. of patients
gabapentin/control
Dose of gabapentin Time of gabapentin administration
Clarke 2009 Pre 60.1 50/29 Canada 40/39 600 mg preoperatively 2 h preoperatively
Clarke 2009 Post 60.9 43/34 Canada 38/39 600 mg postoperatively In the recovery room
Clarke 2010 Pre 60.4 45/28 Canada 38/38 600 mg preoperatively 2 h preoperatively
Clarke 2010 Post 61.7 44/35 Canada 38/38 600 mg postoperatively In postanesthetic care unit
Clarke 2010 60.8 43/27 Canada 22/48 600 mg 2 h preoperatively
Nantha 2011 61.1 52/41 Canada 45/48 800 mg on day 0, and 200 mg
tid for 2 days
2 h preoperatively and postoperatively
Paul 2015 60.7 58/44 Canada 48/54 600 mg 2 h preoperatively
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Inclusion criteria
Studies were considered eligible for inclusion if they met
the following criteria. Study design: RCTs with placebo-
controlled report in English. Population: Patients with
total hip arthroplasties, spinal anaesthesia only, no other
local anaesthetic agent was used. Intervention group:
gabapentin. Control group: placebo. Outcomes: reported
at least one of the following items: postoperative con-
sumption of morphine, pain scores (visual analogue scale
(VAS)), and treatment side effects.
Exclusive criteria
Patients were excluded from the meta-analysis if they
had neoplastic aetiology, infection, traumatic fracture,
metal sensitivity, or mental diseases.
Selection criteria
An eligibility assessment was performed independently
in an unblended standardised manner by two reviewers.
Disagreements between reviewers were resolved by con-
sensus. The Cochrane collaboration’s tool for the assess-
ment of the risk of bias was used [16]. Funnel plots were
drawn to assess the quality of the RCTs.
Data extraction
Two authors (Chao Han and Hong-qiang Jiang, assigned
by Xin-long Ma) independently extracted the data from
the included literature. Trials were analysed and the fol-
lowing data were extracted: first author’s last name; publi-
cation year, gabapentin dose and regimen, type of surgery,
number of patients, pain assessment methods, types and
methods of administration of rescue narcotics, and ad-
verse outcomes.
Statistical analysis
The data were analysed by RevMan 5.3 (The Cochrane
Collaboration, Oxford, UK). Heterogeneity was estimated
depending on the value of P and I2 using the standard chi-
square test. P <0.10 and I2 >50 % were defined as having
significant heterogeneity. Then, a random-effects model
was applied for data analysis. A fixed-effects model was
used when no significant heterogeneity was found. The re-
sults of the meta-analysis studies were expressed as the
standardised mean difference, with 95 % confidence inter-
vals (CIs) for continuous outcomes such as narcotic con-
sumption and pain scores, and relative risk with 95 % CIs
for dichotomous data such as nausea and other side ef-
fects. Differences in means were considered significant
with a P < 0.05.
Results
Literature search
A total of 162 potential studies were identified with the
first search strategy, and 116 were removed as duplicates.
The remainder of the 46 records was screened. After
assessment of the titles and abstracts, 35 articles were
excluded as irrelevant. In total, 11 potentially eligible
studies were identified, six of which were excluded,
leaving five studies that met the eligibility criteria [17–21].
The pooled data consisted of 269 patients in the gabapen-
tin group and 304 patients in the control group. These five
studies were published between the years of 2009 and
2015. Each study included between 20 and 300 patients.
In three trials, gabapentin was given preoperatively only
[18, 20, 21], whereas in the two other trials, gabapentin
Fig. 2 The summary of bias risk of randomised controlled trials
Fig. 3 Forest plot of postoperative narcotic consumption at 24 h
between the two groups
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were administered preoperatively and postoperatively
[17, 19]. “Clarke 2009 Pre” and “Clarke 2009 Post” was
the same trial, in which there were three groups, and
we divided this trial into two different comparisons
(gabapentin vs. placebo preoperatively; gabapentin vs.
placebo postoperatively). “Clarke 2010 Pre” and “Clarke
2010 Post” was also the same trial, in which there were
three groups, and we divided this trial into two differ-
ent comparisons (gabapentin vs. placebo preoperatively;
gabapentin vs. placebo postoperatively).
Study characteristics
The characteristics of the included gabapentin studies are
reported in Table 1. Statistically similar baseline characteris-
tics were observed between the gabapentin and placebo
groups Table 1.
Risk of bias assessment
According to the Cochrane collaboration’s tool for asses-
sing the risk of bias in RCTs, all our included trials have
a low risk for bias Fig. 2.
Outcomes for meta-analysis
Postoperative narcotic requirements at 24 h
Details regarding narcotic consumption at 24 h were
available in four trials [19–21]. There was no significant
heterogeneity (χ2 = 2.10, df = 3, I2 = 0 %, P = 0.55);
therefore, a fixed model was performed. The overall
pooled results from the meta-analysis showed that
compared with placebo, gabapentin could significantly
reduce postoperative narcotic consumption (MD= −6.06,
95 % CI −10.50 to −1.62, P = 0.007; Fig. 3).
Postoperative narcotic requirements at 48 h
Details regarding narcotic consumption at 48 h were avail-
able in seven trials [17–21]. There was no significant
heterogeneity (χ2 = 5.53, df = 6, I2 = 0 %, P = 0.48); therefore,
a fixed model was performed. The overall pooled results
from the meta-analysis showed that compared with pla-
cebo, gabapentin could not significantly reduce postopera-
tive narcotic consumption (MD= 3.80, 95 % CI −8.30 to
0.70, P = 0.10; Fig. 4).
Postoperative VAS (at rest) at 24 h
Six trials reported VAS at 24 h [17, 19–21]. Significant
heterogeneity was not found; therefore, a fixed model
was used (χ2 = 0.89, df = 5, I2 = 0 %, P = 0.97). Compared
with placebo, gabapentin could not significantly re-
duce the VAS at 24 h (MD = 1.44, 95 % CI −0.69 to
3.57, P = 0.18; Fig. 5).
Postoperative VAS (with movement) at 24 h
Six trials reported VAS at 24 h [17, 19–21]. There was
no significant heterogeneity (χ2 = 3.00, df = 5, I2 = 0 %,
P = 0.70); therefore, a fixed model was performed. The
overall pooled results from meta-analysis showed that
compared with placebo, no significant difference was found
in the gabapentin groups (MD= 1.70, 95 % CI −1.96 to
5.35, P = 0.91; Fig. 6).
Postoperative VAS (at rest) at 48 h
Six trials reported VAS at 48 h [17, 19–21]. Significant
heterogeneity was not found; therefore, a fixed model
was used (χ2 = 4.12, df = 5, I2 = 0 %, P = 0.53). The pooled
results showed that compared with placebo, gabapentin
could significantly reduce the VAS at 48 h (MD = −2.63,
95 % CI −4.40 to −0.86, P = 0.004; Fig. 7).
Postoperative VAS (with movement) at 48 h
Six trials reported VAS at 48 h [17, 19–21]. There was
no significant heterogeneity (χ2 = 7.26, df = 5, I2 = 31 %,
P = 0.20); therefore, a fixed model was performed. The
Fig. 5 Forest plot of postoperative VAS (at rest) at 24 h between the
two groups
Fig. 4 Forest plot of postoperative narcotic consumption at 48 h
between the two groups
Fig. 6 Forest plot of postoperative VAS (with movement) at 24 h
between the two groups
Fig. 7 Forest plot of postoperative VAS (at rest) at 48 h between the
two groups
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overall pooled results from the meta-analysis showed
that compared with placebo, no significant difference
was found in the gabapentin groups (MD = 1.47, 95 %
CI −2.28 to 5.21, P = 0.44; Fig. 8).
Adverse effects
The most commonly reported adverse effect in the trials
included in our study was nausea, which was reported in
four studies [19–21]. Significant heterogeneity was not
found; therefore, a fixed model was used (χ2 = 0.19, df = 3,
I2 = 0 %, P = 0.98). Compared with the control group, no
significant difference was found in the gabapentin groups
(relative rate 0.94, 95 % CI 0.75–1.17, P = 0.57; Fig. 9).
Four studies reported the incidence rate of pruritus
[19–21]. Significant heterogeneity was not found; there-
fore, a fixed model was used (χ2 = 1.87, df = 3, I2 = 0 %,
P = 0.60). Compared with the control group, no signifi-
cant difference was found in the gabapentin groups
(relative rate 1.12, 95 % CI 0.72–1.75, P = 0.61; Fig. 10).
Four studies reported the incidence rate of sedation
[19–21]. Significant heterogeneity was not found; there-
fore, a fixed model was used (χ2 = 1.13, df = 3, I2 = 0 %,
P = 0.77). Compared with the control group, no signifi-
cant difference was found in the gabapentin groups
(relative rate 1.10, 95 % CI 0.85–1.42, P = 0.48; Fig. 11).
Three studies reported the incidence rate of dizziness
[19, 20]. Significant heterogeneity was not found; there-
fore, a fixed model was applied (χ2 = 0.36, df = 2, I2 = 0 %,
P = 0.83). Compared with the control group, no significant
difference was found in the gabapentin groups (relative
rate 1.15, 95 % CI 0.74–1.80, P = 0.53; Fig. 12).
Discussion
This work aimed to review the related papers system-
atically to gain a better understanding of the efficacy
of gabapentin in the treatment of postoperative pain
after THA. Our results showed that compared with
the control group, a significant reduction in cumulative
narcotic consumption was found at 24 h postoperatively.
This finding shares the same views with previous system-
atic studies examining the effect of gabapentin in different
surgeries [12, 22, 23].
Another technique used to evaluate the effect of gaba-
pentin in the treatment of pain was to assess the pain
scores. In this part, the 24- and 48-h postoperative VAS
score (at rest or with movement) was chosen as our
point of comparison. However, a significant reduction in
VAS score was only found in the movement group at
48 h postoperatively, when compared with placebo.
There was no significant difference in the rest of the
groups. This finding of our research is different from
those of previous studies [23, 24]. This could be ex-
plained by the discrepancy of the surgical procedure and
the difference of sample sizes.
Nausea is the one of adverse effects in the postopera-
tive period. It is related to many factors, such as the dif-
ferent methods of anaesthesia or opioid use. As shown
in Fig. 9, the rate of nausea appeared to increase in the
control group, but the difference was not statistically sig-
nificant. Gabapentin administration is associated with
decreased postoperative nausea, which is somewhat
similar with the previous research [25]. Regarding other
side effects, such as pruritus, sedation, and dizziness, we
found that the gabapentin group has a similar incident
rate to that of the placebo group. It is still unclear
whether these side effects are dose-related.
As we know it, this study might be the first meta-
analysis regarding gabapentin in the management of
postoperative pain after THA. To overcome the short-
comings of retrospective or observational studies, all of
the included papers were randomised and prospective
studies. The limitations of this study are the various
study designs and the analytical approach, which may
Fig. 8 Forest plot of postoperative VAS (with movement) at 48 h
between the two groups
Fig. 9 Forest plot of incidence of nausea between the two groups
Fig. 10 Forest plot of incidence of pruritus between the two groups
Fig. 11 Forest plot of incidence of sedation between the two groups
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lead to the obvious heterogeneity in those studies. Other
potentially limiting factors of this study include the type
of THA, duration of surgery, and complications, which
could also play a factor in the degree of pain experi-
enced. Nearly all of the included studies were conducted
by anaesthetists; therefore, some details such as surgical
approach, way of incision, fixation method, and variety
of implant were rarely reported in those studies. How-
ever, that information was usually crucial to orthopae-
dics. It is believed that all of these factors have the
ability to change the degree of postoperative pain, so
they need to be taken into account in future studies.
Another limitation was that the dosages and adminis-
tration time of gabapentin were inconsistent; the dose
was 600 mg in some trials and 800 mg in others. How-
ever, our analysis demonstrated that the gabapentin only
had a significant effect on VAS scores in the movement
group at 48 h. Pandey et al. [26] suggested that 600 mg
of gabapentin was the best dose. However, Khan et al.
[27] found that the pain scores were lower in groups re-
ceiving 900 or 1200 mg of gabapentin. We are unable
definitely state what the optimal dosages of gabapentin
are from this meta-analysis, yet it seems as if 600 mg
has the same effect to 800 mg. Therefore, further studies
are needed to be performed to further evaluate the best
dose of gabapentin.
Conclusions
This meta-analysis of prospective studies shows that
gabapentin was efficacious in the reduction of postoper-
ative narcotic requirements and VAS score after THA.
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